Genmab is now planning to expand the antibody’s development in cancer, specifically the existing non-cutaneous T-cell lymphoma and cutaneous T-cell lymphoma clinical programs, and to create a unibody for the HIV virus, by targeting the CD4 receptor.
Worldwide rights to HuMax-CD4 were previously licensed to Merck Serono in August 2005.